Increased levels of IL-6 in the tumour microenvironment and/or mutations of loss-of-function mutations affecting STAT3 negative regulators result in STAT3 hyperactivation in tumour cells (Walter et al., 2009). The gene discussed is STAT3; the disease is neoplasm.